A systematic review and network meta-analysis on comparative efficacy, acceptability, and safety of treatments in acute bipolar mania in youths
Journal of Affective Disorders · 2024
DOI: 10.1016/j.jad.2024.01.067 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Affective Disorders, 2024. Verfasst von Selma Tural Hesapcioglu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Ankara Yildirim Beyazit University, Faculty of Medicine, Department of Child and Adolescent Psychiatry, Ankara, Turkey. Electronic address: selmatura…. Hauptthemen laut MEDLINE: Bipolar Disorder, Antipsychotic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Université de Paris.
Abstract (Originalsprache)
BACKGROUND: The evidence of treatment options' efficacy on acute bipolar manic episodes is relatively less in youths than adults. We aimed to compare and rank the drug's efficacy, acceptability, tolerability, and safety for acute mania in children and adolescents. METHOD: We systematically reviewed the double-blinded, randomized controlled trials (RCTs) comparing drugs or placebo for acute manic episodes of bipolar disorder in children and adolescents using PRISMA guidelines. We searched PubMed/MEDLINE, EMBASE, Web of Science, EBSCO, Scopus, the Cochrane Central Register of Controlled Trials, and https://clinicaltrials.gov from inception until November 20, 2022. Response to treatment was the primary outcome, and random-effects network meta-analyses were conducted (PROSPERO 2022: CRD42022367455). RESULTS: Of 10,134 citations, we included 15 RCTs, including 2372 patients (47 % female), 15 psychotropic drugs, and the placebo. Risperidone 0.5-2.5 mg/day, aripiprazole 30 mg/day olanzapine, quetiapine 400 mg/day, quetiapine 600 mg/day, asenapine 5 mg/day, asenapine 10 mg, ziprasidone, and aripiprazole 10 mg were found to be effective (in comparison with placebo) in children and adolescents, respectively (τ2 = 0.0072, I2 = 10.2 %). The tolerability of aripiprazole 30 mg/day was lower than risperidone 0.5-2.5 mg/day and olanzapine. Oxcarbazepine had the highest discontinuation due to the adverse effects risk ratio. LIMITATIONS: Efficacy ranking of the treatments could be performed by evaluating relatively few RCT results, and only monotherapies were considered. CONCLUSIONS: Efficacy, acceptability, tolerability, and safety are changing with the doses of antipsychotics for children and adolescents with acute bipolar manic episodes. Drug selection and optimum dosage should be carefully adjusted in children and adolescents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ankara Yildirim Beyazit University, Faculty of Medicine, Department of Child and Adolescent Psychiatry, Ankara, Turkey. Electronic address: selmaturalhesapcioglu@aybu.edu.tr.
- Ankara Yildirim Beyazit University, Faculty of Medicine, Department of Child and Adolescent Psychiatry, Ankara, Turkey.
- Ankara Yildirim Beyazit University, Faculty of Medicine, Department of Biostatistics, Ankara, Turkey.
Förderung
- Université de Paris
Zitieren
APA
Tural Hesapcioglu, S., Kasak, M., Abursu, H., Kafali, S., Ceylan, M. F., & Akyol, M. (2024). A systematic review and network meta-analysis on comparative efficacy, acceptability, and safety of treatments in acute bipolar mania in youths. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2024.01.067
Vancouver
Tural Hesapcioglu S, Kasak M, Abursu H, Kafali S, Ceylan MF, Akyol M. A systematic review and network meta-analysis on comparative efficacy, acceptability, and safety of treatments in acute bipolar mania in youths. Journal of Affective Disorders. 2024. doi:10.1016/j.jad.2024.01.067
BibTeX
@article{TuralHesapcioglu2024,
author = {Tural Hesapcioglu, Selma and Kasak, Meryem and Abursu, Helin and Kafali, Seda and Ceylan, Mehmet Fatih and Akyol, Mesut},
title = {A systematic review and network meta-analysis on comparative efficacy, acceptability, and safety of treatments in acute bipolar mania in youths},
journal = {Journal of Affective Disorders},
year = {2024},
doi = {10.1016/j.jad.2024.01.067}
}
EUVIMED